500 articles · 20 / page
A novel sixth-gen hs-cTnT assay with a 13 ng/L threshold safely identified twice as many low-risk MI patients at ED presentation vs fifth-gen assays, achieving >99.5% NPV in multinational validation.
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
A randomized trial shows left bundle branch pacing significantly reduces the risk of pacing-induced cardiomyopathy and improves cardiac function compared to right ventricular pacing in high-risk patients.
A multiregistry analysis reveals that massive LVH in pediatric HCM is linked to early diagnosis, sarcomeric mutations, and heightened risks of arrhythmias, heart failure, and mortality. Nearly 25% of patients show significant LVH regression
The LEGEND trial demonstrates that a high-sensitivity troponin-based rule-out strategy significantly reduces hospital length of stay and cardiac testing while safely excluding acute myocardial infarction in emergency department patients.
A high-volume aortic center study reveals 93.6% technical success and 82.6% survival at 60 months with f/bEVAR for complex aneurysms, though reinterventions remain frequent.
A French cohort study reveals 44% of women receiving postpartum antihypertensives after HDP develop chronic hypertension within 10 years, signaling urgent gaps in long-term cardiovascular risk monitoring.
A study reveals that RV-PA coupling, measured by TAPSE/sPAP ratio, significantly predicts outcomes in HFrEF patients during GDMT up-titration, highlighting its potential as a treatment target.
PhysioSync-HF trial reveals CSP is inferior to BiVP for HFrEF patients with LBBB, challenging its role as a first-line resynchronization therapy despite cost benefits.
Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.
ORBITA-2 reveals PCI’s superior placebo-controlled angina relief in focal vs. diffuse coronary artery disease, with physiological disease patterns guiding treatment decisions.
Researchers identify JNK2 as a key mediator in gut-heart crosstalk, linking intestinal permeability to atrial fibrillation pathogenesis through inflammatory stress signals, offering new therapeutic targets.
The HeartSync-LBBP trial reveals left bundle-branch pacing reduces the composite of death or heart failure hospitalization by 74% compared to biventricular pacing, with significantly higher super-response rates in patients with reduced ejec
A nationwide study reveals that eclampsia patients face a 6.9-fold increased risk of cardiovascular disease readmission within the first year postpartum, with stroke risk nearly 13 times higher than normotensive patients. These findings und
A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful
This groundbreaking research identifies WNT5a-mediated aberrant actin filament dynamics as the novel mechanism driving cardiac pathogenic phenotypes in Emery-Dreifuss muscular dystrophy, opening new therapeutic avenues for this rare but dev
The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in
Researchers identify HEG1 as a critical flow-sensitive endothelial protein that regulates blood pressure through CUL3-mediated degradation of PHACTR1, linking reduced shear stress in hypertension to impaired NO production and vascular dysfu
A large observational study reveals that cardiogenic shock patients receiving temporary mechanical circulatory support at regional referral centers before transfer to hub centers experience significantly higher device-related adverse events
![Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy](https://news.medxy.ai/wp-content/uploads/2026/04/d43c8ff0-6629-4944-bc15-78efd79810d7-600x600.jpg)
A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher b
Open language-specific specialty feeds and department pages.